Quarterly report pursuant to Section 13 or 15(d)

Financial Instruments - Additional Information (Detail)

v3.23.1
Financial Instruments - Additional Information (Detail) - USD ($)
1 Months Ended
Sep. 14, 2021
Sep. 30, 2022
Mar. 31, 2023
Dec. 31, 2022
Nov. 16, 2021
Schedule Of Available For Sale Securities [Line Items]          
Contingent consideration, current     $ 190,000 $ 8,067,000  
Sale of stock price per share         $ 27.74
Other Assets          
Schedule Of Available For Sale Securities [Line Items]          
Strategic investment     2,750,000 $ 2,750,000  
PandoLogic Merger Agreement [Member]          
Schedule Of Available For Sale Securities [Line Items]          
Contingent consideration, current     $ 190,000    
Pandologic Ltd [Member]          
Schedule Of Available For Sale Securities [Line Items]          
Business acquisition, effective date of acquisition Sep. 14, 2021        
Business acquisition, percentage of ownership interests acquired 100.00%        
Business acquisition, name of acquired entity PandoLogic, Ltd. (“PandoLogic”)        
Business acquisition, date of acquisition agreement Jul. 21, 2021        
Stock Consideration [Member] | PandoLogic Merger Agreement [Member]          
Schedule Of Available For Sale Securities [Line Items]          
Sale of stock price per share     $ 20.53    
Minimum [Member]          
Schedule Of Available For Sale Securities [Line Items]          
Contingent earnout   $ 10,825,000      
Maximum [Member] | Pandologic Ltd [Member]          
Schedule Of Available For Sale Securities [Line Items]          
Contingent consideration, current $ 65,000,000